Skip to main content
. Author manuscript; available in PMC: 2014 Feb 14.
Published in final edited form as: JAMA. 2012 Feb 22;307(8):804–812. doi: 10.1001/jama.2012.169

Figure 4. Cost-effectiveness acceptability frontier.

Figure 4

The cost-effectiveness acceptability frontier depicts the strategy with the highest expected net benefit for a given willingness to pay threshold. The no vaccination strategy has the highest expected net benefit at values of ≤$35,000/QALY, PCV13 substituted for PPSV23 in current recommendations is favored from $40,000-50,000/QALY, and PCV13 at ages 50 and 65 is favored at higher willingness to pay thresholds >$50,000/QALY.